1,587 results on '"Finke, Jürgen"'
Search Results
152. Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation
153. MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GVHD
154. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party.
155. Cellular and humoral SARS-CoV2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
156. Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation
157. Hematological Neoplasia
158. Medical Oncology
159. Hematology and Hemostasis
160. Special Diagnostics
161. Particular Treatment Procedures
162. Standardized Treatment Protocols
163. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
164. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
165. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery
166. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR
167. Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: “real life” evaluation
168. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
169. Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
170. Favourable outcomes of double‐hit/double‐expressor lymphoma and high‐grade B‐cell lymphoma, not otherwise specified after early dose‐intensive treatment and up‐front autologous stem cell transplantation: a single‐centre retrospective experience
171. Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100
172. Supplement to: Antilymphocyte globulin for prevention of chronic graft-versus-host disease.
173. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
174. Favourable outcomes of poor prognosis diffuse large B‐cell lymphoma patients treated with dose‐dense Rituximab, high‐dose Methotrexate and six cycles of CHOP‐14 compared to first‐line autologous transplantation
175. Thiotepa‐based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia—A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
176. Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial
177. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
178. Late-onset hemophagocytic lymphohistiocytosis (HLH) in an adult female with Griscelli syndrome type 2 (GS2)
179. Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
180. Radiation-Free Allogeneic Conditioning with Fludarabine, Carmustine, and Thiotepa for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies Necessitating Enhanced Central Nervous System Activity
181. Marrow versus Blood-Derived Stem Cell Grafts for Allogeneic Transplantation from Unrelated Donors in Patients with Active Myeloid Leukemia or Myelodysplasia
182. Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study
183. Improvement in Oral Chronic Graft-versus-Host Disease with the Administration of Effervescent Tablets of Topical Budesonide—An Open, Randomized, Multicenter Study
184. Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS)
185. Evaluation of Trends in Outcome over 2 Decades of Patients with Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplantation from Unrelated Donors: An ALWP/EBMT Analysis
186. A Two-Part, Single- and Two-Arm Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of KRP203 in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
187. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius
188. Genome-wide Profiling in AML Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation
189. Horizontal DNA Transfer from Donor to Host Cells as an Alternative Mechanism of Epithelial Chimerism after Allogeneic Hematopoietic Cell Transplantation
190. Allogeneic Stem Cell Transplantation in Multiple Myeloma
191. Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma
192. Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)
193. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
194. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
195. Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9
196. Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation
197. Expansion of NKG2A −LIR1 − Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic Cell Transplantation
198. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
199. How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party
200. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.